RenovoRx Expands to 12 Centers with $1.1M Revenue, Raises $10M
RenovoRx generated $1.1 million in 2025 RenovoCath sales, with 12 U.S. cancer centers active and 21 more evaluating it, tripling its pipeline. The firm raised $10 million to bring cash to $13 million, has randomized 104 of 114 Phase III TIGeR-PaC patients and targets mid-2026 enrollment completion with 2027 readout.
1. 2025 Commercial Launch and Revenue
RenovoRx generated $1.1 million in RenovoCath sales during its first full commercialization year. Adoption expanded to 12 active U.S. cancer centers, while 21 additional centers are evaluating or preparing to activate the device, marking a threefold increase in its near-term pipeline since Q1 2025.
2. Strengthened Balance Sheet
In late 2025 the company completed a financing that raised $10 million in gross proceeds (net $9.2 million), boosting cash-on-hand to $13 million. This infusion supports planned go-to-market expansion and progression toward breakeven operations in 2026.
3. Phase III TIGeR-PaC Trial Progress
RenovoRx has randomized 104 of the required 114 patients in its pivotal TIGeR-PaC study, with 72 events observed. The trial remains on track for full enrollment by mid-2026 and a final data readout in 2027, after which participating centers may convert to commercial RenovoCath users.